8-K: Telomir Pharmaceuticals Appoints New CFO Following Resignation

Telomir Pharmaceuticals has appointed Michelle Yanez as its new Chief Financial Officer, effective June 18, 2024, following the resignation of Nathan Fuentes.

Summary

• Telomir Pharmaceuticals announced the resignation of its Chief Financial Officer, Nathan Fuentes, effective June 18, 2024.
• The company has appointed Michelle Yanez as the new Chief Financial Officer, also effective June 18, 2024.
• Ms. Yanez has served as the company's part-time Corporate Controller since May 2022.
• She also has experience as CFO of MIRA Pharmaceuticals and has held leadership positions at BioDelivery Sciences International.
• Ms. Yanez's annual base salary will be $137,500, and she is eligible for a sign-on bonus related to a change of control and a discretionary annual bonus.
• Mr. Fuentes will receive $62,500 in severance payments over three months, and his stock options will remain exercisable.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate transition with a new CFO appointment. The company has acted quickly to fill the position with an experienced candidate, which is a positive sign. However, the resignation of the previous CFO introduces a slight element of uncertainty.

Positives

• The company has quickly filled the CFO position with an experienced financial executive.
• Michelle Yanez has a strong background in public and private biotech companies.
• Ms. Yanez's experience includes corporate governance and financial offerings.
• The transition appears to be smooth with a clear separation agreement for the outgoing CFO.

Negatives

• The resignation of the previous CFO, Nathan Fuentes, may raise some concerns.
• The company is incurring severance costs of $62,500 for the outgoing CFO.

Risks

• The company is undergoing a change in key financial leadership.
• There is a risk of disruption during the transition period.
• The company's future performance will depend on the new CFO's ability to execute the company's financial strategy.

Future Outlook

The company has not provided any specific forward-looking statements in this document, but the appointment of a new CFO is a key step in the company's ongoing operations.

Management Comments

• The resignation of Mr. Fuentes was not based on any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

Industry Context

The appointment of a new CFO is a common occurrence in the biotech and pharmaceutical industries, especially for companies in the development stage. The experience of the new CFO in similar companies is a positive sign.

Comparison to Industry Standards

• The salary of $137,500 for the CFO is within the range for similar roles in pre-clinical stage pharmaceutical companies, though it is at the lower end of the range for public companies.
• The severance package for the outgoing CFO is standard practice.
• Michelle Yanez's experience at MIRA Pharmaceuticals (Nasdaq: MIRA) and BioDelivery Sciences International (Nasdaq: BDSI) provides a strong benchmark for her capabilities.

Management Changes

Stakeholder Impact

• Shareholders may react to the change in financial leadership.
• Employees will be working under a new CFO.
• Creditors and suppliers will be dealing with a new financial contact.

Next Steps

• Michelle Yanez will assume her duties as CFO.
• The company will continue its operations with the new financial leadership.
• The company may need to update its financial policies and procedures to align with the new CFO's expertise.

Key Dates

Keywords

Chief Financial Officer, CFO, executive appointment, resignation, Michelle Yanez, Nathan Fuentes, pharmaceuticals, biotech, corporate governance, severance